Companies in #Rare Endocrine Disorders
Found 3 companies operating in this sector.
Camurus is a Swedish specialty pharmaceutical company developing and commercializing innovative medicines based on its proprietary FluidCrystal technology platform for long-acting injectable drug delivery. The company focuses on rare diseases, oncology, and CNS disorders.
Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.
Late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders, with a lead program in classic congenital adrenal hyperplasia.